BME

PowerSchool Announces First Quarter Financial Results

Retrieved on: 
星期二, 五月 7, 2024
Primary, Secondary, Education, Data Management, Technology, Software, Artificial Intelligence, Internet, Momentum, Knowledge, CFO, AI, School, Parent, Learning, Red Hat, Enrollment, GAAP, Schoology, Workload, BETT, International school, K-12, Generative, Visalia Unified School District, Ecosystem, International, ARR, Responsibility, Behavior, Assessment, Microsoft, Student, Treasury, SIS, Synthetic media, BME, UNESCO, Pearson Education, Growth, Toledo City School District

PowerSchool Holdings, Inc. (NYSE: PWSC) ("PowerSchool" or the “Company”), the leading provider of cloud-based software for K-12 education in North America, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • PowerSchool Holdings, Inc. (NYSE: PWSC) ("PowerSchool" or the “Company”), the leading provider of cloud-based software for K-12 education in North America, today announced financial results for its first quarter ended March 31, 2024.
  • “We opened 2024 with a strong first quarter in which we met our revenue guidance and exceeded the high end of our profitability guidance.
  • Finally, PowerSchool joined the UNESCO Global Education Coalition to support the digital transformation of education worldwide.
  • Commenting on the Company’s results, Eric Shander, PowerSchool President and CFO, added, “We demonstrated continued operational excellence and execution in line with our strategy during the first quarter.

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Retrieved on: 
星期三, 三月 13, 2024
COL7, FAP, Cancer, Patient, APC, Mouse, ALM, Ribosome, BME, Gastrointestinal disease, OTC, Skin, Polyp (medicine), Therapy, Kidney, Pharmaceutical industry

BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.

Key Points: 
  • BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.
  • Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases.
  • ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
  • The drug candidate is expected to shortly enter into Phase I development in healthy volunteers.

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

Retrieved on: 
星期三, 三月 13, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, COL7, FAP, Cancer, Patient, APC, Mouse, ALM, Ribosome, BME, Gastrointestinal disease, OTC, Skin, Polyp (medicine), Therapy, Kidney, Pharmaceutical industry

Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.

Key Points: 
  • Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.
  • Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases.
  • ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
  • The drug candidate is expected to shortly enter into Phase I development in healthy volunteers.

$430,000 Awarded to Visionary Black Social Impact Leaders by BMe Community

Retrieved on: 
星期一, 四月 1, 2024
L.O.V.E, BME, Knowledge, McKnight Foundation, George Kaiser

MIAMI, April 1, 2024 /PRNewswire/ -- BMe Community proudly announces its 2024 BMe Vanguard Awards.

Key Points: 
  • MIAMI, April 1, 2024 /PRNewswire/ -- BMe Community proudly announces its 2024 BMe Vanguard Awards.
  • The BMe Vanguard program brings inspiring and trusted Black leaders into a community that fosters their well-being, financial empowerment, collaboration, and positive social impact.
  • "BMe Vanguards come from all walks of life but share one authentic action-oriented love for humanity," said Trabian Shorters, Co-founder and CEO of BMe Community.
  • Since its inception in 2013, BMe has given over $4 Million in angel grants, launching 260 social impact initiatives and supporting 160 more.

LLYC reports revenue and EBITDA growth for 2023

Retrieved on: 
星期四, 三月 21, 2024
Growth, Media, ESG, Corporate Affairs, Marketing, BME, Complutense University of Madrid, Partner, Corporate welfare, RDI

This advancement, fueled by a blend of organic and inorganic growth, surpassed the targets outlined in the budget.

Key Points: 
  • This advancement, fueled by a blend of organic and inorganic growth, surpassed the targets outlined in the budget.
  • Throughout 2020-2023, LLYC has magnified its operating revenues by a factor of 2.1 and its EBITDA by a factor of 2.2.
  • In 2023, LLYC's revenue distribution by business unit was as follows:
    Europe accounted for 33% of operating revenues and 37.7% of EBITDA.
  • In 2023, revenue from innovation activities accounted for 11.4% of Deep Digital's total revenue.

LLYC Announces the Acquisition of Lambert Global

Retrieved on: 
星期一, 二月 19, 2024
Acquisition, Greenberg Traurig, Capital market, Marketing, Kirk Norcross, Growth, PR, PRWeek, BME, Corporate Affairs, History, Creativity, LLP, Provocation

GRAND RAPIDS, Mich. and MADRID, Spain, Feb. 19, 2024 (GLOBE NEWSWIRE) -- LLYC (BME:LLYC), a global Corporate Affairs and Marketing consulting firm, today announced the acquisition of Lambert Global, a strategic communications firm that specializes in public relations, investor relations, and integrated marketing.

Key Points: 
  • GRAND RAPIDS, Mich. and MADRID, Spain, Feb. 19, 2024 (GLOBE NEWSWIRE) -- LLYC (BME:LLYC), a global Corporate Affairs and Marketing consulting firm, today announced the acquisition of Lambert Global, a strategic communications firm that specializes in public relations, investor relations, and integrated marketing.
  • Founded in 1998, Lambert Global pioneered the integrated PR and IR agency model, and has enjoyed 25 years of uninterrupted growth.
  • Jeff Lambert will join LLYC's Global Executive Committee, while Mike Houston and Jeff Lambert will both join the U.S. Executive Committee.
  • Now operating as Lambert by LLYC, Lambert will create value-added synergies with the Company’s entire international network.

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology

Retrieved on: 
星期一, 二月 19, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, BME, Dermatology, Novo Nordisk, ALM, Multimedia, Patient, Partnership, Vaccine

Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.

Key Points: 
  • Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828.
  • Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases.
  • Novo Nordisk will receive an upfront payment as well as additional development and commercial milestone payments and tiered royalties based upon future global sales.
  • NN-8828 is a first-in-class in dermatology, high affinity monoclonal antibody that targets the cytokine IL-21 and has been developed by Novo Nordisk up to Phase ll in non-dermatological indications.

Holaluz delivers on Normalised EBITDA guidance, reaching 3M€ for FY2023

Retrieved on: 
星期三, 一月 31, 2024
Certification, ESG, Delinquent, Global warming potential, UNEF, COGS, Subscription business model, DNA, Excellent, Distributed generation, EMS, Normalization, ISO, Virtual power plant, VPP, Energy management, EV, CO2, EM, Next Generation, Perception, Economics, Acquisition, Sale, Electricity, Solar, APPA, BME, Cost, Woman, Renewable energy

Barcelona, January 31, 2024 (GLOBE NEWSWIRE) -- Holaluz-Clidom S.A. (BME:HLZ) delivers on Normalised EBITDA guidance, reaching 3M€ for FY2023

Key Points: 
  • Barcelona, January 31, 2024 (GLOBE NEWSWIRE) -- Holaluz-Clidom S.A. (BME:HLZ) delivers on Normalised EBITDA guidance, reaching 3M€ for FY2023
    Holaluz doubled its solar market share in 2023 to over 3% by the end of December from 1.6% in 2022.
  • Holaluz, an energy transition company aiming to decarbonise the economy, today provided an update on Q4 2023 KPIs as well as a forecast on normalised EBITDA for the financial year 2023.
  • The company expects to meet the low range ( 3-5 million euros) of normalised EBITDA forecasts for the 2023 financial year according to the business plan published on 31 October, reaching 3M€.
  • Furthermore, in December 2023, Holaluz obtained ISO 14000 certification for its environmental management system (EMS), which reiterates its environmental commitment.

Holaluz receives Adigital's Algorithmic Transparency Certification to promote responsible and ethical AI

Retrieved on: 
星期二, 一月 23, 2024
UNESCO, BME, OECD, Artificial intelligence, Trust, Algorithmic transparency, AI, ESG, Algorithm, Good, Digital economy, Organization, Council, Certification, Medical device

Madrid, January 23, 2024 (GLOBE NEWSWIRE) -- Holaluz-Clidom S.A. (BME:HLZ) receives Adigital's Algorithmic Transparency Certification to promote responsible and ethical AI

Key Points: 
  • Madrid, January 23, 2024 (GLOBE NEWSWIRE) -- Holaluz-Clidom S.A. (BME:HLZ) receives Adigital's Algorithmic Transparency Certification to promote responsible and ethical AI
    The certificate, a pioneer in Europe, promotes the creation and implementation of responsible artificial intelligence systems, through transparency and explainability.
  • The OECD has decided to include Adigital certification in its Good Practice Guide to ensure that Artificial Intelligence tools have a responsible and efficient regulatory framework.
  • The Algorithmic Transparency Certificate of Adigital , the Spanish Association of the Digital Economy, completed its pilot phase with three Spanish companies, Holaluz, Adevinta (InfoJobs), and Shakers, to be the first to obtain this certificate.
  • The certificate promotes the creation and implementation of responsible artificial intelligence systems, through transparency and explainability.

LLYC's operating income up 14% to €83.1 MM in 2023

Retrieved on: 
星期四, 一月 25, 2024
Region, Learning, BME, Literature, DNA, Knowledge, Human resources, AMP, Hobby, Complutense University of Madrid, Corporate Affairs, Innovation, Corporate finance, Chair, PepsiCo, Education minister, MBA, Market, Acquisition, Harvard Business School, Doctor of Philosophy, Director general, Marketing, General Electric, Energy, Growth, Management

LLYC's performance in 2023 surpassed the objectives outlined in its strategic plan for the year.

Key Points: 
  • LLYC's performance in 2023 surpassed the objectives outlined in its strategic plan for the year.
  • The firm's organic growth led to an 8% increase in operating revenues and gross operating income.
  • It now accounts for 34.5% of operating income and 28.1% of the firm's recurring EBITDA.
  • The new budget forecasts an 8% increase in operating income to 90 million euros and recurring EBITDA to 20 million euros.